SAGE Therapeutics Inc (NASDAQ:SAGE) has recently been included in a filing by Jacob Gottlieb‘s Visium Asset Management. According to the 13G filing with the US Securities and Exchange Commission, Visium currently owns 5.9% of SAGE Therapeutics, which represent around 5.9% of the company’s outstanding stock. This compares with the 902,948 shares that Visium disclosed in its last 13F filing, for the third quarter of 2015.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Visium Asset Management, | 1,893,009 | 1,893,009 | 1,893,009 | 5.9% | ||
| JG Asset, | 1,893,009 | 1,893,009 | 1,893,009 | 5.9% | ||
| Jacob Gottlieb | 1,893,009 | 1,893,009 | 1,893,009 | 5.9% |
Follow Jacob Gottlieb's Visium Asset Management
Page 1 of 11 SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Sage
Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
78667J108
(CUSIP Number)
February 1, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
x Rule 13d-1(b)**
x Rule 13d-1(c)**
¨ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
| ** | This Schedule is being filed pursuant to Rule 13d-1(b) with respect to Visium Asset Management, LP, JG Asset, LLC and Jacob Gottlieb, and pursuant to Rule 13d-1(c) with respect to certain advisory clients of Visium Asset Management, LP. |
The information required on the remainder of this cover page shall not be deemed to be filed for the
purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 2 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 2 of 11 Pages |
| 1 | NAMES OF I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only) Visium Asset Management, LP | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER (a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF United States | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER None | ||||
| 6 | SHARED VOTING POWER 1,893,009 (See Item 4) | |||||
| 7 | SOLE DISPOSITIVE POWER None | |||||
| 8 | SHARED DISPOSITIVE POWER 1,893,009 (See Item 4) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,893,009 (See Item 4) | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ¨ Not Applicable | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT 5.9% | |||||
| 12 | TYPE OF REPORTING PERSON* IA, PN | |||||
Page 2 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 3 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 3 of 11 Pages |
| 1 | NAMES OF I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only) JG Asset, LLC | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER (a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF United States | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER None | ||||
| 6 | SHARED VOTING POWER 1,893,009 (See Item 4) | |||||
| 7 | SOLE DISPOSITIVE POWER None | |||||
| 8 | SHARED DISPOSITIVE POWER 1,893,009 (See Item 4) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,893,009 (See Item 4) | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ¨ Not Applicable | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT 5.9% | |||||
| 12 | TYPE OF REPORTING PERSON* HC, OO | |||||
Page 3 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 4 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 4 of 11 Pages |
| 1 | NAMES OF I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only) Jacob Gottlieb | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER (a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF United States | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER None | ||||
| 6 | SHARED VOTING POWER 1,893,009 (See Item 4) | |||||
| 7 | SOLE DISPOSITIVE POWER None | |||||
| 8 | SHARED DISPOSITIVE POWER 1,893,009 (See Item 4) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,893,009 (See Item 4) | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ¨ Not Applicable | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT 5.9% | |||||
| 12 | TYPE OF REPORTING PERSON* HC, IN | |||||
Page 4 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 5 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 5 of 11 Pages |
| Item 1(a) | Name of Issuer: |
Sage Therapeutics, Inc.
| (b) | Address of Issuers Principal Executive Offices: |
215 First Street
Cambridge, MA 02142
| Item 2 | (1) (3) This statement is filed on behalf of the following: |
| (1) | Visium Asset Management, LP, a Delaware limited partnership (VAM), with its principal business office c/o Visium Asset Management, LP, 888 Seventh Avenue, New York, NY 10019. |
| (2) | JG Asset, LLC, a Delaware limited liability company (JG Asset), with its principal business office c/o Visium Asset Management, LP, 888 Seventh Avenue, New York, NY 10019. JG Asset is the General Partner of VAM. |
| (3) | Jacob Gottlieb (Gottlieb), a natural person, with his principal business office c/o Visium Asset Management, LP, 888 Seventh Avenue, New York, NY 10019. Gottlieb is the Managing Member of JG Asset. |
| (d) | Title of Class of Securities: |
Common Stock, $0.0001 par value per share
| (e) | CUSIP Number: |
78667J108
Page 5 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 6 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 6 of 11 Pages |
| Item 3 | If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: |
| ¨ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). | |
| ¨ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). | |
| ¨ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). | |
| ¨ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 1,561,899a-8). | |
| x | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);* | |
| ¨ | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | |
| x | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);* | |
| ¨ | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
| ¨ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 1,561,899a-3); | |
| ¨ | Group, in accordance with §240.13d-1(b)(1)(ii)(J). | |
| * | VAM is an investment adviser as described above and JG Asset and Gottlieb are each a parent holding company or control person as described above. |
| Item 4 | Ownership: |
VAM
| (a) | Amount Beneficially Owned: |
By virtue of its position as investment
manager to pooled investment vehicles, VAM may be deemed to beneficially own the 1,893,009 shares of the Companys Common Stock beneficially owned by the pooled investment vehicle.
| (b) | Percent of Class: |
5.9%
Page 6 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 7 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 7 of 11 Pages |
| (c) | Number of Shares as to which person has: |
| (i) | sole power to vote or to direct vote: |
| None |
| (ii) | shared power to vote or to direct vote: |
| 1,893,009 shares |
| (iii) | sole power to dispose or direct disposition of: |
| None |
| (iv) | shared power to dispose or to direct disposition of: |
| 1,893,009 shares |
JG Asset
| (a) | Amount Beneficially Owned: |
By virtue of its position as General Partner
to VAM, JG Asset may be deemed to beneficially own the 1,893,009 shares of the Companys Common Stock beneficially owned by VAM.
| (b) | Percent of Class: |
5.9%
| (c) | Number of Shares as to which person has: |
| (i) | sole power to vote or to direct vote: |
| None |
| (ii) | shared power to vote or to direct vote: |
| 1,893,009 shares |
| (iii) | sole power to dispose or direct disposition of: |
| None |
Page 7 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 8 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 8 of 11 Pages |
| (iv) | shared power to dispose or to direct disposition of: |
1,893,009 shares
Gottlieb
| (a) | Amount Beneficially Owned: |
By virtue of his position as the Managing
Member of JG Asset, Gottlieb may be deemed to beneficially own the 1,893,009 shares of the Companys Common Stock beneficially owned by JG Asset.
| (b) | Percent of Class: |
5.9%
| (c) | Number of Shares as to which person has: |
| (i) | sole power to vote or to direct vote: |
| None |
| (ii) | shared power to vote or to direct vote: |
| 1,893,009 shares |
| (iii) | sole power to dispose or direct disposition of: |
| None |
| (iv) | shared power to dispose or to direct disposition of: |
| 1,893,009 shares |
VAM, JG Asset and Gottlieb disclaim beneficial ownership as to the securities, except to the
extent of his or its pecuniary interests therein. Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that any of the other individual officers and members of VAM or JG Asset is, for any
purpose, the beneficial owner of any of the Securities.
Page 8 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 9 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 9 of 11 Pages |
| Item 5 | Ownership of Five Percent or Less of a Class: |
Not Applicable
| Item 6 | Ownership of More than Five Percent on Behalf of Another Person: |
The
securities reported on this Schedule 13G, which are beneficially owned by VAM, JG Asset and Gottlieb, are owned by advisory clients of VAM, none of whom own more than 5% of the class.
| Item 7 | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: |
Not Applicable
| Item 8 | Identification and Classification of Members of the Group: |
Not Applicable
| Item 9 | Notice of Dissolution of Group: |
Not Applicable
Page 9 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 10 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 10 of 11 Pages |
| Item 10 | Certification: |
By signing below I certify that, to the best
of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 10, 2016
| VISIUM ASSET MANAGEMENT, LP | ||
| By: JG Asset, LLC, its General Partner | ||
| By: | /s/ Mark Gottlieb | |
| Mark Gottlieb | ||
| Authorized Signatory | ||
| JG ASSET, LLC | ||
| By: | /s/ Mark Gottlieb | |
| Mark Gottlieb | ||
| Authorized Signatory | ||
| JACOB GOTTLIEB | ||
| By: | /s/ Mark Gottlieb | |
| Mark Gottlieb | ||
| Authorized Signatory | ||
Page 10 of 11 Pages
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Page 11 of 11 SEC Filing
| CUSIP No. 78667J108 | Page 11 of 11 Pages |
Exhibit A
AGREEMENT
The undersigned agree that this Schedule 13G dated February 10, 2016 relating to the Common Stock, $0.0001 par value per share of Sage Therapeutics, Inc.
shall be filed on behalf of the undersigned.
| VISIUM ASSET MANAGEMENT, LP | ||
| By: JG Asset, LLC, its General Partner | ||
| By: | /s/ Mark Gottlieb | |
| Mark Gottlieb | ||
| Authorized Signatory | ||
| JG ASSET, LLC | ||
| By: | /s/ Mark Gottlieb | |
| Mark Gottlieb | ||
| Authorized Signatory | ||
| JACOB GOTTLIEB | ||
| By: | /s/ Mark Gottlieb | |
| Mark Gottlieb | ||
| Authorized Signatory | ||
Page 11 of 11 Pages
